Sign in
Taking peoplePhase 4

Iron through a vein or by mouth for anaemia and depression after caesarean

Compares iron given by vein or by mouth for postpartum depression after caesarean.

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France23 sites in 1 countryChoose a country to see its sites
Registry title
Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression
Status
Recruiting
Phase
Phase 4
People taking part
2,860 people, planned
Started
22 Oct 2025
Expected to end
30 Oct 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ferric carboxymaltose IV
  • TIMOFÉROL®
Record updated
21 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women who gave birth by caesarean and have moderate anaemia from low iron soon after delivery. It compares iron given through a vein with iron tablets, and looks at postpartum depression.

Age
18 to 64 years
Sex
Women only
Disease stage
Moderate iron deficiency anaemia after a caesarean (planned or emergency), with Hb between 8.0 g/dL and 10.0 g/dL within 72 hours after delivery. Baby born at 32 weeks of pregnancy or later. Women must be staying in the postpartum maternity ward.
Earlier treatment
Women who take iron supplements long-term (outside pregnancy) cannot join. Women currently treated with medicine or Electro Convulsion Therapy (ECT) for depression or bipolar disorder cannot join.
Biomarker or test result
Ferritinemia ≤ 100 ng/mL OR transferrin saturation ≤ 20%. EPDS depression score below 13 right after birth, with a "never" answer to question 10.

Main reasons for not taking part

  • Stillbirth or death of the newborn
  • Body weight below 35kg (77 lb (35 kg)) or above 100kg (220 lb (100 kg))
  • Biermer disease, hemochromatosis, homozygous sickle cell disease or thalassemia
  • Allergy or contra-indication to IV or oral iron, severe asthma, severe kidney or liver disease, or active acute infection
  • Schizophrenia, poor understanding of French, or being under legal protection

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Ferritinemia ≤ 100 ng/mL OR transferrin saturation ≤ 20% measured after postoperative Hb level measurement
  • EPDS score in the immediate postpartum <13 with a "never" answer to question n°10

Who cannot take part

  • Contra-indication to the studied drugs (IV or oral iron)
  • Women currently treated with medication or with Electro Convulsion Therapy (ECT) for depression or bipolar disorders
  • Biermer disease
  • Homozygous sickle cell disease or thalassemia
  • Known hypersensitivity or allergy to the studied drugs (IV or oral iron)
  • Any known severe renal or liver disorder
  • Active acute infection
  • Participation in another clinical trial involving an intervention with the following risks:; A change (increase or decrease in value) in Haemoglobin measured at 2 months postpartum OR; A change in EPDS score measured at 2 and 6 months postpartum OR; A trial exploring an intervention with a specific anaphylactic risk (reported as a potential adverse events in the protocol of the other trial) administered during the postpartum hospitalization period
  • Stillbirth or neonatal death
  • Last body weight available before inclusion (measured at the end of pregnancy or in postpartum) < 35kg or > 100kg
  • Hemochromatosis
  • Chronic iron supplementation (outside pregnancy)
  • Severe asthma (with daily background treatment)
  • Diagnosis of schizophrenia or physical and intellectual state incompatible with a reliable self-evaluation
  • Poor understanding of the French language
  • Legal protection (curatorship or tutorship)

Other criteria

  • Pre-inclusion criteria:
  • Age ≥18 years
  • Caesarean delivery (elective or in emergency)
  • Gestational age at delivery ≥ 32 weeks
  • 8.0 g/dL ≤ postoperative Hb level ≤ 10.0 g/dL measured within 72 hours postpartum
  • Informed consent form signed
  • Hospitalization in the postpartum maternity ward
  • National social security coverage including AME

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The objectif of the IRON-DEP Study is to assess the efficacy of intravenous (IV) versus oral iron treatment on the prevalence of postpartum depression (PPD) in women with moderate iron deficiency anemia after caesarean delivery.

The 2 groups in the trial

  • Intravenous ironTreatment being tested

    Women in the experimental arm will receive an IV iron infusion within 5 days after delivery

  • Oral ironExisting treatment, for comparison

    Women in the comparator arm will receive oral iron supplementation for 8 weeks after delivery

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Treatment of Anaemia After Caesarean With Intravenous Versus Oral Iron and Postpartum Depression: a Multicentric Randomized Open-labelled Controlled Trial
Plain-language title
Iron through a vein or by mouth for anaemia and depression after caesareanGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Fit questions
Built from NCT06833788, who can take part
Record updated
21 September 2026